Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover
Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expands its autoimmune drug portfolio.
Argenx bought another company for $2.2 billion to get new medicines that help fight diseases where the body attacks itself. When a big company buys a smaller one for a lot of money, it usually means they think those medicines could be really successful and help their business grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.